CDK2 and neoplasm: CDK2 activated MYBL2 by phosphorylation, leading to anti-PD-1 resistance in OC, but the CDK2 inhibitor CVT-313 suppressed MYBL2 in A2780 and SKOV3 OC cells and circumvented anti-PD-1 resistance of murine ID8 OC by modulation of the tumor microenvironment[143].